507 related articles for article (PubMed ID: 24690555)
1. Influence of PPh₃ moiety in the anticancer activity of new organometallic ruthenium complexes.
Sáez R; Lorenzo J; Prieto MJ; Font-Bardia M; Calvet T; Omeñaca N; Vilaseca M; Moreno V
J Inorg Biochem; 2014 Jul; 136():1-12. PubMed ID: 24690555
[TBL] [Abstract][Full Text] [Related]
2. DNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(ii) terpyridine complexes.
Lazić D; Arsenijević A; Puchta R; Bugarčić ŽD; Rilak A
Dalton Trans; 2016 Mar; 45(11):4633-46. PubMed ID: 26855406
[TBL] [Abstract][Full Text] [Related]
3. New π-arene ruthenium(II) piano-stool complexes with nitrogen ligands.
Grau J; Noe V; Ciudad C; Prieto MJ; Font-Bardia M; Calvet T; Moreno V
J Inorg Biochem; 2012 Apr; 109():72-81. PubMed ID: 22387934
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium(II)/(III) complexes of 4-hydroxy-pyridine-2,6-dicarboxylic acid with PPh3/AsPh3 as co-ligand: impact of oxidation state and co-ligands on anticancer activity in vitro.
Kamatchi TS; Chitrapriya N; Lee H; Fronczek CF; Fronczek FR; Natarajan K
Dalton Trans; 2012 Feb; 41(7):2066-77. PubMed ID: 22183160
[TBL] [Abstract][Full Text] [Related]
5. New ruthenium(II) arene complexes of anthracenyl-appended diazacycloalkanes: effect of ligand intercalation and hydrophobicity on DNA and protein binding and cleavage and cytotoxicity.
Ganeshpandian M; Loganathan R; Suresh E; Riyasdeen A; Akbarsha MA; Palaniandavar M
Dalton Trans; 2014 Jan; 43(3):1203-19. PubMed ID: 24177707
[TBL] [Abstract][Full Text] [Related]
6. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
7. An investigation on new ruthenium(II) hydrazone complexes as anticancer agents and their interaction with biomolecules.
Alagesan M; Bhuvanesh NS; Dharmaraj N
Dalton Trans; 2014 Apr; 43(16):6087-99. PubMed ID: 24519473
[TBL] [Abstract][Full Text] [Related]
8. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, X-ray structure, physicochemical properties and anticancer activity of mer and fac Ru(iii) triphenylphosphine complexes with a benzothiazole derivative as a co-ligand.
Richert M; Walczyk M; Cieślak MJ; Kaźmierczak-Barańska J; Królewska-Golińska K; Wrzeszcz G; Muzioł T; Biniak S
Dalton Trans; 2019 Jul; 48(28):10689-10702. PubMed ID: 31241117
[TBL] [Abstract][Full Text] [Related]
10. Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents.
Ludwig G; Kaluđerović GN; Rüffer T; Bette M; Korb M; Block M; Paschke R; Lang H; Steinborn D
Dalton Trans; 2013 Mar; 42(11):3771-4. PubMed ID: 23340605
[TBL] [Abstract][Full Text] [Related]
11. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
[TBL] [Abstract][Full Text] [Related]
12. DNA interaction and cytotoxicity studies of new ruthenium(II) cyclopentadienyl derivative complexes containing heteroaromatic ligands.
Moreno V; Font-Bardia M; Calvet T; Lorenzo J; Avilés FX; Garcia MH; Morais TS; Valente A; Robalo MP
J Inorg Biochem; 2011 Feb; 105(2):241-9. PubMed ID: 21194624
[TBL] [Abstract][Full Text] [Related]
13. Influence of carboxylic acid functionalities in ruthenium (II) polypyridyl complexes on DNA binding, cytotoxicity and antioxidant activity: synthesis, structure and in vitro anticancer activity.
Sathiya Kamatchi T; Chitrapriya N; Kim SK; Fronczek FR; Natarajan K
Eur J Med Chem; 2013 Jan; 59():253-64. PubMed ID: 23234855
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure and biological evaluation of bis salicylaldehyde-4(N)-ethylthiosemicarbazone ruthenium(iii) triphenylphosphine.
Prabhakaran R; Kalaivani P; Jayakumar R; Zeller M; Hunter AD; Renukadevi SV; Ramachandran E; Natarajan K
Metallomics; 2011 Jan; 3(1):42-8. PubMed ID: 21132183
[TBL] [Abstract][Full Text] [Related]
15. Mixed ligand palladium(II) complexes of 6-methoxy-2-oxo-1,2-dihydroquinoline-3-carbaldehyde 4N-substituted thiosemicarbazones with triphenylphosphine co-ligand: synthesis, crystal structure and biological properties.
Ramachandran E; Senthil Raja D; Bhuvanesh NS; Natarajan K
Dalton Trans; 2012 Nov; 41(43):13308-23. PubMed ID: 22864662
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of DNA binding, DNA cleavage, protein binding, radical scavenging and in vitro cytotoxic activities of ruthenium(II) complexes containing 2,4-dihydroxy benzylidene ligands.
Mohanraj M; Ayyannan G; Raja G; Jayabalakrishnan C
Mater Sci Eng C Mater Biol Appl; 2016 Dec; 69():1297-306. PubMed ID: 27612830
[TBL] [Abstract][Full Text] [Related]
17. Antiparasitic activities of novel ruthenium/lapachol complexes.
Barbosa MI; Corrêa RS; de Oliveira KM; Rodrigues C; Ellena J; Nascimento OR; Rocha VP; Nonato FR; Macedo TS; Barbosa-Filho JM; Soares MB; Batista AA
J Inorg Biochem; 2014 Jul; 136():33-9. PubMed ID: 24727183
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic Ruthenium(II) Complexes Containing a Dangling Pyridine: Selectivity for Diseased Cells Mediated by pH-Dependent DNA Binding.
Sangeetha S; Murali M
Inorg Chem; 2022 Feb; 61(6):2864-2882. PubMed ID: 35099196
[TBL] [Abstract][Full Text] [Related]
19. Promising anticancer mono- and dinuclear ruthenium(III) dithiocarbamato complexes: systematic solution studies.
Nagy EM; Nardon C; Giovagnini L; Marchiò L; Trevisan A; Fregona D
Dalton Trans; 2011 Nov; 40(44):11885-95. PubMed ID: 21971872
[TBL] [Abstract][Full Text] [Related]
20. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
